By targeting the BCR-ABL oncoprotein, imatinib (brand name Gleevec) is able to induce a complete cytogenetic remission in the majority of chronic phase CML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.